Kidney Cancer News and Research

RSS

Kidney cancer is usually defined is a cancer that originates in the kidney. The two most common types of kidney cancer, reflecting their location within the kidney, are renal cell carcinoma (RCC) and urothelial cell carcinoma (UCC) of the renal pelvis.

Researchers discover biological pathway signature of ccRCC

By examining expression of every human gene in clear cell renal cell carcinoma compared to normal kidney cells, researchers at Mayo Clinic's campus in Florida have discovered gene signatures they say explain much of the biology of this common and difficult-to-treat kidney cancer.

19 May 2010

Cancer Research UK launches new cancer centre in Leeds

LEEDS today joins a unique chain of Cancer Research UK Centres that are being launched across the UK.

18 May 2010

152 research and training grants awarded to researchers at 93 institutions nationwide

The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 152 new national research and training grants totaling $50,717,000 in the first of two grants cycles for 2010. The grants, primarily to early career researchers, cover a broad range of investigator-initiated ideas at 93 institutions nationwide, from whether cadmium exposure increases the risk of endometrial cancer, to studies of plant and bacterial-bourne compounds, to a study on a protein called survivin that could lead to novel drugs targeting prostate cancer.

18 May 2010

IMBio receives regulatory concurrence from FDA to market OCL 500 microspheres in the U.S.

IMBiotechnologies Ltd., a privately held biotechnology company focused on developing medical device products for use in the area of embolotherapy, today announced that it has received regulatory concurrence from the United States Food and Drug Administration to market its lead product, Occlusin 500 Artificial Embolization Device in the U.S. for the treatment of unresectable/inoperable hypervascularized tumours.

12 May 2010

Total kidney removal not beneficial for elderly patients with confined kidney tumors

A new study indicates that patients aged 75 years or older who have confined kidney tumors do not live longer if they have their entire kidney removed. The research reveals that these patients typically have other medical problems of greater significance and that many should receive more conservative cancer-related care, such as observation or treatments that spare the noncancerous parts of their kidneys. The study is published early online in CANCER, a peer-reviewed journal of the American Cancer Society.

10 May 2010

Investigators demonstrate safety and efficacy of targeted medication to shrink advanced kidney cancers

A multicenter team of investigators led by the University of California, San Diego School of Medicine has demonstrated, for the first time, the safety and efficacy of a targeted medication to shrink advanced kidney cancers prior to partial kidney removal and reconstruction. Their findings were published in the April 2010 online edition of BJU International.

6 May 2010

S*BIO, Onyx Pharmaceuticals expand development, commercialization collaboration for JAK2 Inhibitors

S*BIO Pte Ltd and Onyx Pharmaceuticals, Inc. today announced the expansion of their development collaboration and option and license commercialization agreement for S*BIO's novel JAK2 inhibitors, SB1518 and SB1578, also known as ONX 0803 and ONX 0805, respectively. The expanded agreement builds upon the development and commercialization collaboration between the two companies announced in January 2009.

5 May 2010

AVEO Pharmaceuticals presents data on potential utility of Notch1-specific monoclonal antibody at 101st AACR

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced preclinical data which demonstrate that its Notch1-specific monoclonal antibody is a highly potent inhibitor of Notch1 function in both in vitro and in vivo models. These data were presented today at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 in Washington, D.C.

22 Apr 2010

EORTC 30904 study: Conservative surgery not inferior to radical renal surgery

The latest results from the European Organisation for Research and Treatment of Cancer (EORTC) 30904 study were presented in a plenary session today at the Anniversary European Association of Urology Congress in Barcelona, which showed that conservative surgery is not inferior to radical renal surgery or nephrectomy.

19 Apr 2010

BeaconEquity.com releases investment report featuring Antigenics

BeaconEquity.com announces an investment report featuring Antigenics Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

15 Apr 2010

ErbB3 program development candidate selection triggers $5M milestone payment to AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced it has received a $5 million milestone payment from Biogen Idec International GmbH, a subsidiary of Biogen Idec, Inc., for the selection of the first humanized antibody development candidate from its ErbB3 program.

15 Apr 2010

AVEO Pharmaceuticals to present preclinical data from translational research platform at AACR 2010

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that preclinical data from its translational research platform and antibody pipeline will be presented during six poster sessions at the American Association for Cancer Research 101st Annual Meeting 2010 being held April 17-21, 2010, in Washington, D.C.

13 Apr 2010

Hepatitis C infection increases risk for developing kidney cancer

Physicians at Henry Ford Hospital have found that infection with the hepatitis C virus increases the risk for developing kidney cancer.

8 Apr 2010

Pair of proteins excreted in urine could lead to earlier diagnosis of kidney cancer: Researchers

Studying patients with kidney cancer, a team of researchers at Washington University School of Medicine in St. Louis has identified a pair of proteins excreted in the urine that could lead to earlier and more accurate diagnosis of the disease.

8 Apr 2010

Newer treatments, closer monitoring of childhood cancer may improve longevity

Although more children today are surviving cancer than ever before, young patients successfully treated in the 1970s and 80s may live a decade less, on average, than the general population, according to a study from Dana-Farber Cancer Institute and the Harvard School of Public Health.

7 Apr 2010

Childhood cancer survivors may not survive long says new study

Children who have survived a cancer are at a higher risk of an early death says two new studies. The first report published in the April 6th issue of the Annals of Internal Medicine, said that there was a cumulative effect of the disease, a childhood cancer and its treatment on the risk of death in 15 year old patients who have been cancer free for at least 5 years.

6 Apr 2010

NHS cancer patients to receive latest and best treatments available

Cancer patients on the National Health Service may soon be offered expensive life extending drugs which are currently denied to them. David Cameron has proposed on behalf of the Conservatives that the drugs that are licensed and prescribed by the health consultant of the patient should be made available to the cancer patient, irrespective of the NHS rationing.

5 Apr 2010

Gene linked to kidney cancer in children discovered

Cancer Research UK-funded scientists have identified two genes linked to Wilms' tumour - a type of childhood kidney cancer - according to research published in Clinical Cancer Research.

2 Apr 2010

NICE leaves many patients with rarer forms of cancer without drugs

The National Institute for Health and Clinical Excellence (NICE) is failing to follow its own guidance aimed at making live-extending treatments available on the NHS, leaving many patients with rarer forms of cancer without drugs that could prolong their lives, a campaign group has said.

18 Mar 2010

Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009

Idera Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2009.

10 Mar 2010